fashion -WSS

fashion

author：fashion 2025-09-30 17:02:28 - browse：6

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Flagship Pioneering startup Sonata Therapeutics lays off 21

WSS

FDA warns medical device makers about rise in fabricated data

Lupron, used to halt puberty in children, may cause lasting health problems

New CMS data security rules will hurt Medicare, Medicaid research

'Screen and refer' systems are hurting patients

As AI regulations shape up, health tech startups beg for clarity

STAT wants to know your pick for a great summer read or listen

entertainment

fashion

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT wants to know your pick for a great summer read or listen

In Memoriam: Notable people who died in 2023

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

The high cost of giving birth even with insurance

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Medical leaders decry Supreme Court decision on affirmative action

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

focus

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

What affirmative action's end means to a medical student

FDA warns medical device makers about rise in fabricated data

Prescription digital therapeutics are key to pharma’s future

Fatty liver disease was alleviated by Lilly’s ‘triple

Wikipedia

entertainment

hotspot

focus